NCT02499146 2026-02-11
Palbociclib Pharmacokinetics Study In Postmenopausal Chinese Women With ER (+), HER2 (-) Advanced Breast Cancer
Pfizer
Phase 1 Completed
Clinical Trials
15 trialsNCT04728035 2024-07-26
Study of Irinotecan Liposome Injection in Patients With Advanced Breast Cance
CSPC Ouyi Pharmaceutical Co., Ltd.
Phase 1 Completed
NCT03052634 2023-12-18
A Study of RC48-ADC in Subjects With Advanced Breast Cancer
RemeGen Co., Ltd.
Phase 1/2 Completed
NCT06098599 2023-10-24
Comparing the Pharmacokinetic Profile of LY01612 and CAELYX® in Chinese Subjects With Advanced Breast Cancer
Luye Pharma Group Ltd.
Phase 1 Completed
NCT04097756 2023-05-01
A Phase I Study of LX-039 Tablets
Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.
Phase 1 Completed
NCT02069093 2017-02-13
Open-label, Phase II Study of Stomatitis Prevention With a Steroid-based Mouthwash in Post-menopausal Women With Estrogen-receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)- Metastatic or Locally Advanced Breast Cancer
Novartis
Phase 2 Completed
NCT00494481 2016-09-30
E3 Breast Cancer Taxotere Combination
Sanofi
Phase 2 Completed
NCT00454805 2016-08-03
AZD2171 in Addition to Fulvestrant in Patients With Advanced Breast Cancer.
AstraZeneca
Phase 2 Completed
NCT00754325 2016-05-26
Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-positive Advanced Breast Cancer Previously Treated With an Aromatase Inhibitor
Bristol-Myers Squibb
Phase 2 Completed
NCT00452673 2015-03-24
Phase I Study of Dasatinib (BMS-354825) and Capecitabine for Women With Advanced Breast Cancer
Bristol-Myers Squibb
Phase 1 Completed
NCT00106145 2015-01-30
A Notch Signalling Pathway Inhibitor for Patients With Advanced Breast Cancer (0752-014)
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT00562458 2013-02-05
Non-interventional Study to Evaluate Arimidex in Postmenopausal Women With Advanced Breast Cancer
AstraZeneca
Completed
NCT00327769 2011-01-25
Faslodex Advanced Breast Cancer Local Chinese Study
AstraZeneca
Phase 3 Completed
NCT00328120 2010-11-17
Faslodex 500mg Multiple Dose Tolerability Study in BC Patients
AstraZeneca
Phase 1 Completed
NCT00635713 2009-04-10
Second Line Breast Cancer Trial
AstraZeneca
Phase 3 Completed